Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J.W. Sweetenham
The 23-Gene Gene Expression-Based Assay Does Not Predict Interim Pet Scan Results After Abvd in Advanced Stage Classical Hodgkin Lymphoma in the Us Intergroup S0816 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
A Gene Expression-Based Score to Predict Interim Pet Positivity in Hodgkin Lymphoma Patients Treated With Abvd
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Interim FDG-PET Does Not Predict Outcome in Advanced-Stage Hodgkin Lymphoma Patients Treated With BEACOPP
British Journal of Haematology
Hematology
Ebeacopp With or Without Rituximab in Interim-Pet-Positive Advanced-Stage Hodgkin Lymphoma: Updated Results of the International, Randomized Phase 3 GHSG Hd18 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
PET-guided Treatment in Advanced-Stage Hodgkin Lymphoma: Yes but Which One?
Oncotarget
Oncology
Interim FDG-PET Has No Value in Selecting Patients Who Require Treatment Modification in Both Early- And Advanced-Stage Hodgkin Lymphoma
British Journal of Haematology
Hematology
Quantitative Assessment of Interim PET in Hodgkin Lymphoma: An Evaluation of the qPET Method in Adult Patients in the RAPID Trial
PLoS ONE
Multidisciplinary
Consolidation Radiotherapy Could Be Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After Abvd. Final Analysis of the Randomized Hd0607 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
9225 Hodgkin Lymphoma Treatment With ABVD in the US and the EU: Neutropenia Occurrence and Impaired Chemotherapy Delivery
European Journal of Cancer, Supplement
Cancer Research
Oncology
The Glasgow Prognostic Score at Diagnosis Is an Independent Predictor of Survival in Advanced Stage Classical Hodgkin Lymphoma
British Journal of Haematology
Hematology
